Pharmacotherapy of borderline personality disorder
The present American Psychiatric Association guideline
59
states that symptom targeted pharmacotherapy is an important adjunctive treatment. This therapy is based on Siever and Davis'
23
dimensions of affective instability (treated with selective serotonin reuptake inhibitor [SSRIs] or monoamine oxidase inhibitors), impulsive aggression (treated with SSRIs or mood stabilisers), and cognitive–perceptive disturbances (treated with low dose antipsychotics). By contrast the UK's NICE guidelines
15
state that drug treatment should generally be avoided, except in a crisis, and then given for no longer than 1 week. The World Federation of Societies of Biological Psychiatry guidelines
60
stated that moderate evidence exists for antipsychotic drugs being effective for cognitive–perceptual and impulsive–aggressive symptoms, that some evidence exists for SSRIs being effective for emotional dysregulation, and that some evidence exists for mood stabilisers being effective for emotional dysregulation and impulsive–aggressive symptoms. The second Cochrane review
61
saw no evidence for the efficacy of SSRIs, but reported that mood stabilisers could diminish affective dysregulation and impulsive–aggressive symptoms in patients with borderline personality disorder, and that antipsychotic drugs could improve cognitive–perceptual symptoms and affective dysregulation. Some concern exists that several of the trials showing positive outcomes provide unreliable data.
25
The most recent guidelines for treatment of borderline personality disorder from Australia's National Health and Medical Research Council (NHMRC)
62
again reviewed the scientific literature and included a series of meta-analyses. They concluded that “overall pharmacotherapy did not appear to be effective in altering the nature and course of the disorder. Evidence does not support the use of pharmacotherapy as first line or sole treatment for BPD [borderline personality disorder]”.
The NICE and NHMRC guideline committees agreed with the Cochrane review
61
and other reviews
63
and meta-analyses
64
that evidence existed that some second generation antipsychotics (notably aripiprazole and olanzapine) and mood stabilisers (notably topiramate, lamotrigine, and valproate) could slightly reduce borderline personality disorder symptoms over the short term. However, as guideline groups they needed to consider the risks and possible benefits of evidence-based treatments. The fact that most of the recommended drugs have substantial long-term risks whereas other treatments such as psychosocial interventions do not have these risks affected their recommendations
65
The situation is complicated by the fact that drugs are used very frequently in the treatment of borderline personality disorder despite the scarcity of evidence for their use. Zanarini and colleagues
4
reported that 78% of patients with borderline personality disorder were on drugs for more than 75% of the time during a 6 year period. Additionally, 37% of these patients were on three or more drugs. In view of this situation clinicians should be guided towards the drugs with at least some evidence (ie, major tranquillisers and mood stabilisers) and away from those with less evidence (ie, SSRIs, tricyclic antidepressants, and benzodiazepines). NICE
66
have argued that the assumption that drug treatment is justified at all is without evidence and their prescription should not be encouraged. The NICE guidelines
15
explicitly state that if patients have no comorbid illness, efforts should be made to reduce or stop pharmacotherapy (
panel 3).